INCY vs. VTRS: Incyte vs. Viatris Stock Comparison

November 11, 2026

How do Incyte (INCY) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Incyte (INCY) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Incyte (INCY) and Viatris (VTRS)
Profile Item	INCY	VTRS
Name	Incyte Corp.	Viatris Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	24.39 billion USD	22.83 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	November 4, 1993	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

INCY

VTRS

GSPC

Incyte (INCY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Incyte (INCY) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Incyte (INCY) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Total Return (1Y)	14.06%	108.98%
Total Return (3Y, Annualized)	32.03%	36.75%
Total Return (5Y, Annualized)	12.69%	11.59%

Risk Profile

Drawdown History

INCY

VTRS

GSPC

Incyte (INCY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Incyte (INCY) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Volatility (1Y, Annualized)	33.19%	32.53%
Beta (5Y)	0.78	0.86
Max Drawdown (5Y)	-40.50%	-45.69%
Avg. Volume (3M)	1.58M	8.87M

Risk-Adjusted Performance

Risk-Return Positioning

INCY and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Sharpe Ratio (1Y)	0.29	3.22
Sortino Ratio (1Y)	0.46	5.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Incyte (INCY) reports 7.84%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.84%

Max: 109.18%
INCY: 7.84%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Incyte (INCY) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Incyte (INCY) reports 6.71%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.71%

Max: 18.05%
INCY: 6.71%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

Incyte (INCY) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Incyte (INCY) at 33.72% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

33.72%

Max: 83.12%
INCY: 33.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Incyte (INCY) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
ROE (TTM)	7.84%	-4.21%
ROA (TTM)	17.78%	2.91%
Net Margin (TTM)	6.71%	-4.13%
Operating Margin (TTM)	33.72%	13.85%
Gross Margin (TTM)	56.02%	41.13%

Growth

Revenue Growth

Incyte (INCY) at 21.22% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Incyte (INCY) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Incyte (INCY) reports EPS growth of 4,173.33%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Incyte (INCY) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Revenue Growth (YoY)	21.22%	-2.98%
Revenue Growth (3Y CAGR)	14.84%	-4.20%
EPS Growth (YoY)	4,173.33%	--
EPS Growth (3Y CAGR)	61.56%	--

Financial Strength

Current Ratio (MRQ)

Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.84

Max: 25.13
Q3: 12.13
Median: 5.52
INCY: 3.84
Q1: 2.47
Min: 0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

Incyte (INCY) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Viatris (VTRS) at 0.99 sits in the higher-leverage quartile.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
INCY: 0.01
Min: 0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Incyte (INCY) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Current Ratio (MRQ)	3.84	1.55
Debt / Equity (MRQ)	0.01	0.99
Net Debt / EBITDA	-1.88	2.64

Dividends

Dividend Yield (TTM)

Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Incyte (INCY) pays no dividend (payout 0.00%).

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

INCY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Incyte (INCY) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
Dividend Yield (TTM)	0.00%	2.53%
Dividend Payout Ratio (TTM)	0.00%	960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Incyte (INCY) trades at 61.05 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

61.05

Max: 85.34
INCY: 61.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

Incyte (INCY) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; INCY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Incyte (INCY) at 4.06 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.06

Max: 58.18
Q3: 25.77
Median: 7.30
INCY: 4.06
Q1: 3.01
Min: 0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

Incyte (INCY) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile against book while Incyte (INCY) at 4.33 is valued near its industry’s middle — VTRS is cheaper on assets, though weigh it against ROE and asset quality.

INCY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.33

Max: 13.53
Q3: 6.54
INCY: 4.33
Median: 3.25
Q1: 1.69
Min: -5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

Incyte (INCY) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Incyte (INCY) and Viatris (VTRS)
Metric	INCY	VTRS
P/E Ratio (TTM)	61.05	--
P/S Ratio (TTM)	4.06	1.55
P/B Ratio (MRQ)	4.33	1.67
Free Cash Flow Yield (TTM)	5.28%	13.84%